The DOI matches its Crossref record.
Positive Results for Tazemetostat in Follicular Lymphoma
Abstract
A recently reported clinical trial indicates that the EZH2 inhibitor tazemetostat is effective against relapsed or refractory follicular lymphoma. Three of 28 patients with EZH2 mutations had complete responses, and 17 had partial responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently, the arginine methyltransferase PRMT5 has been implicated in driving neoplastic growth of multiple tumours including B cell lymphoma, multiple myeloma, breast cancer and glioblastoma 171-178 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [171]
Citations
Cited by
Sorted by citations
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Carbone, A., Roulland, S., Gloghini, A., Younes, A., von Keudell, G., López‐Guillermo, A., & Fitzgibbon, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0132-x · Cited by 303
Bugide, S., Gupta, R., Green, M. R., & Wajapeyee, N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102718118 · Cited by 86
B cells in chronic graft-versus-host disease
McManigle, W. C., Youssef, A., & Sarantopoulos, S. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.03.003 · Cited by 81
Li, C., Wang, Y., Gong, Y., Zhang, T., Huang, J., Tan, Z. W., & Xue, L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01045-1 · Cited by 82
Metadata
- Venue
- Cancer Discovery
- Published
- 2018-08-01
- Volume
- 8
- Issue
- 8
- Pages
- OF3-OF3
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4241004197
- Cited by
- 8
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2021: 2 · 2019: 4
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Keywords
- tazemetostat, follicular lymphoma, EZH2 inhibitors, EZH2 mutation, relapsed/refractory lymphoma, complete response, partial response, clinical trial results
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Positive Results for Tazemetostat in Follicular Lymphoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-nb2018-088
- The paper
- Positive Results for Tazemetostat in Follicular Lymphoma. (2018). Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-nb2018-088
